ClinicalTrials.Veeva

Menu

Association Between Subtypes of Anti Citrullinated Peptide Antibodies and Lung Damage in Rheumatoid Arthritis (ACPPPA)

U

University Hospital Center of Martinique

Status

Completed

Conditions

Rheumatoid Arthritis

Treatments

Other: Descriptive

Study type

Observational

Funder types

Other

Identifiers

NCT03832374
15/E/27

Details and patient eligibility

About

Rheumatoid arthritis is a genuine systemic disease associated with diffuse interstitial pneumopathy and bronchial disorders. According to the literature review, the prevalence of PID on thoracic CT scan is one-third of patients. Diffuse interstitial pneumopathy is responsible for a significant morbidity and mortality, is currently under-diagnosed and its treatment is poorly codified. The lung seems to have a central role in the genesis of rheumatoid arthritis. It also appears that some subtypes of anti citrullinated peptide antibodies are preferentially present in the lungs.

The hypothesis behind our project is that one or more subtypes of anti citrullinated peptide antibodies with a preferential tropism for the lung would attack the parenchyma and pulmonary airways.

Currently, there are no data on interstitial pneumopathy in black and Afro-Caribbean subjects with rheumatoid arthritis.

Enrollment

77 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient with rheumatoid arthritis ACR/EULAR 2010
  • Patient with a higher age or equal to 18
  • Patient receiving social security
  • Patient giving his free and informed written consent

Exclusion criteria

  • Patient with overlap syndrome with another autoimmune disease
  • Patients with known severe cardiopulmonary pathology
  • Woman who is pregnant and breast feeding
  • Patient with language difficulties or understanding

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems